IP Library Granted Patent US 9,351,995
Granted Patent B1
US 9,351,995 · App. 13/460,426 · Granted May 31, 2016

Compositions and methods of enhancing wound healing

Inventor: Kevin Powers (Maitland, FL)
Assignee: RED OAX HOLDINGS, LLC
A61K33/10A61K9/0043A61K33/00A61K33/06A61K33/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,351,995
App. No.
13/460,426
Granted
May 31, 2016
Kind
B1
Abstract

The present invention relates to ionic compositions for enhancing wound healing, particularly in the sinonasal cavity. The ionic components of the composition can include potassium, calcium, rubidium, zinc, bromide, and magnesium in an isotonic solution. In other embodiments, the ionic components of the composition can include magnesium, bromide, sulfate, sodium, and chloride. Methods of enhancing wound healing, enhancing sinonasal mucosal healing, promoting mucosal reciliation, and debriding tissue by administering the compositions of the present invention are also presented.

Claims (61)

1. A sterile isotonic solution for enhancing wound healing in mucosal tissues in a mammalian subject consisting essentially of:

a therapeutically effective amount of potassium ions;

a therapeutically effective amount of rubidium ions;

a therapeutically effective amount of calcium ions;

a therapeutically effective amount of zinc ions;

a therapeutically effective amount of magnesium ions;

a therapeutically effective amount of bromide ions;

a therapeutically effective amount of counterions wherein the counterions are selected from the group consisting of citrate, chloride, bromide, sulfate, hydroxide, bicarbonate, carbonate, phosphate, lactate, glutamate, acetate and combinations thereof; and

a pharmaceutically acceptable carrier;

wherein tonicity of the solution is 0.9%.

2. The solution of claim 1 , wherein the pharmaceutically acceptable carrier is water.

3. The solution of claim 1 , wherein the amount of potassium ions is between about 0.02% to about 3.0% (w/v).

4. The solution of claim 1 , wherein the amount of rubidium ions is between about 0.0001% to about 4.0% (w/v).

5. The solution of claim 1 , wherein the amount of calcium ions is between about 0.0000055 to about 1.3% (w/v).

6. The solution of claim 1 , wherein the amount of zinc ions is between about 0.0000057% to about 2.12% (w/v).

7. The solution of claim 1 , wherein the amount of magnesium ions is between about 0.0075 to about 1.14% (w/v).

8. The solution of claim 1 , wherein the amount of bromide ions is between about 0.0002% to about 2.6% (w/v).

9. A sterile isotonic solution for enhancing wound healing in mucosal tissues in a mammalian subject consisting essentially of:

a therapeutically effective amount of potassium ions;

a therapeutically effective amount of rubidium ions;

a therapeutically effective amount of calcium ions;

a therapeutically effective amount of zinc ions;

a therapeutically effective amount of magnesium ions;

a therapeutically effective amount of bromide ions;

a therapeutically effective amount of counterions wherein the counterions are selected from the group consisting of citrate, chloride, bromide, sulfate, hydroxide, bicarbonate, carbonate, phosphate, lactate, glutamate, acetate and combinations thereof;

a therapeutically effective amount of citric acid; and

a pharmaceutically acceptable carrier;

wherein tonicity of the solution is 0.9%.

10. The solution of claim 9 , wherein the pharmaceutically acceptable carrier is water.

11. The solution of claim 9 , wherein the amount of potassium ions is between about 0.02% to about 3.0% (w/v).

12. The solution of claim 9 , wherein the amount of rubidium ions is between about 0.0001% to about 4.0% (w/v).

13. The solution of claim 9 , wherein the amount of calcium ions is between about 0.0000055 to about 1.3% (w/v).

14. The solution of claim 9 , wherein the amount of zinc ions is between about 0.0000057% to about 2.12% (w/v).

15. The solution of claim 9 , wherein the amount of magnesium ions is between about 0.0075 to about 1.14% (w/v).

16. The solution of claim 9 , wherein the amount of bromide ions is between about 0.0002% to about 2.6% (w/v).

17. A sterile isotonic solution for enhancing wound healing in mucosal tissues in a mammalian subject consisting essentially of:

a therapeutically effective amount of potassium ions;

a therapeutically effective amount of rubidium ions;

a therapeutically effective amount of calcium ions;

a therapeutically effective amount of zinc ions;

a therapeutically effective amount of magnesium ions;

a therapeutically effective amount of bromide ions;

a therapeutically effective amount of counterions;

a therapeutically effective amount of sulfate ions;

a therapeutically effective amount of chloride ions;

a therapeutically effective amount of citric acid;

a therapeutically effective amount of citrate; and

a pharmaceutically acceptable carrier;

wherein tonicity of the solution is 0.9%.

18. The solution of claim 17 , wherein the pharmaceutically acceptable carrier is water.

19. The solution of claim 17 , wherein the amount of potassium ions is between about 0.02% to about 3.0% (w/v).

20. The solution of claim 17 , wherein the amount of rubidium ions is between about 0.0001% to about 4.0% (w/v).

21. The solution of claim 17 , wherein the amount of calcium ions is between about 0.0000055 to about 1.3% (w/v).

22. The solution of claim 17 , wherein the amount of zinc ions is between about 0.0000057% to about 2.12% (w/v).

23. The solution of claim 17 , wherein the amount of magnesium ions is between about 0.0075 to about 1.14% (w/v).

24. The solution of claim 17 , wherein the amount of bromide ions is between about 0.0002% to about 2.6% (w/v).

25. The solution of claim 17 , wherein the amount of sulfate ions is between about 0.000078% to about 4.5% (w/v).

26. The solution of claim 17 , wherein the amount of chloride ions is about 0.42% (w/v).

27. The solution of claim 17 , wherein the amount of citric acid is between about 0.01% to about 0.1% (w/v).

28. The solution of claim 17 , wherein the amount of citrate is between about 0.03% to about 4.7% (w/v).

29. The solution of claim 9 , wherein the amount of citric acid is between about 0.01% to about 0.1% (w/v).

Assignments (2)
CHANGE OF NAME Recorded Jan 22, 2013
From: ENTENT CARE HOLDINGS, LLC
To: RED OAX HOLDINGS, LLC
Reel/Frame 029673/0628 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2012
From: POWERS, KEVIN
To: ENTENT CARE HOLDINGS, LLC
Reel/Frame 028542/0175 →
Continuity (1)
Provisional Application 61480764 · Apr 29, 2011